Notice of Interim Results
The Company will provide a live presentation of its results via the
The Company is committed to ensuring that there are appropriate communication structures for all elements of its shareholder base so that its strategy, business model and performance are clearly understood.
• Questions can be submitted pre-event via your IMC dashboard or at any time during the live presentation via the "Ask a Question" function. Although the Company may not be able to answer every question it receives, it will address the most prominent within the confines of information already in the public domain. Responses to the Q&A from the live presentation will be published at the earliest opportunity on the IMC platform. No inside information will be given at the presentation.
• Investor feedback can also be submitted directly to management post-event (please see below for contact details).
Investors can sign up to
Investors who have already registered and added to meet the Company will be automatically invited.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
The Directors of
For further information please contact:
+44 (0) 7831 675747
+44 (0) 7747 625506
+44 (0) 7776 234600
Aquis Exchange Corporate Adviser:
+44 (0) 20 7213 0880
+44 (0) 20 3815 8880
- ends -
Notes to Editors
The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and the Company is now focussed upon delivering Sol to a commercial partner within 12-18 months of listing.
The Company originated from the
The majority of conventional cancer treatments (other than surgery) on the market are chemotherapy or radiotherapy based. These are non-selective by nature and highly toxic to healthy tissue as well as tumours. Accordingly, treatment can only be delivered in carefully controlled doses over a limited period of time. To address this problem directly, the Company has developed sophisticated formulation and prodrug targeting technologies to deliver treatment specifically to the tumour. Prodrugs are chemically modified versions of pharmacologically active agents which only become active when they reach a target, thus reducing generalised toxicity in normal tissues, whilst enabling higher doses to reach a target and therefore increase efficacy.
For more information on the Company please visit: www.incanthera.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the